Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Haloperidol 2 mg Formulations in Healthy Volunteers
NCT04411940Phase 1Completed
- Sponsor
- Cycle Pharmaceuticals
- Start
- Nov 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of haloperidol in schizophrenia and Tourette syndrome (TS) (2 arms), sponsored by Cycle Pharmaceuticals. Primary endpoints: Maximum Plasma Concentration at 192 hours, Area Under the Curve to Last Timepoint at 192 hours and 1 more. Started Nov 2019; status: completed.
02
Drugs
haloperidol
03
Conditions
schizophreniaTourette syndrome (TS)
Beyond the preview
Go deeper on NCT04411940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04411940.